| November 03, 2005
Dr. Susan
Froshauer, President and Chief Executive
Officer
of Rib-X Pharmaceuticals, will present
at the
CIBC World Markets 16th Annual Healthcare
Conference
Monday
November 7, 2005
8:00am
New York City
An audio webcast of Dr. Froshauer’s
remarks will be available live. You
can access the webcast at: http://conferences.cibcwm.com/health05,
source code: november
About Rib-X Pharmaceuticals, Inc.
Rib-X Pharmaceuticals is a product
driven small molecule drug discovery
and development company focused on
the structure-based design of new
classes of antibiotics. The Company’s
drug discovery strategy exploits its
proprietary high-resolution crystal
structure of the 50S subunit of the
ribosome, which performs an essential
role in the fundamental process of
protein synthesis. The 50S is the
target for many clinically valuable
classes of antibiotics, including
those used to treat infections caused
by serious, drug-resistant, community-acquired
and hospital pathogens. The Company’s
integrated research approach combines
state of the art, computational analysis,
x-ray crystallography, medicinal chemistry,
microbiology and biochemistry, allowing
for the rapid synthesis of new classes
of antibiotics, which avoid typical
antibiotic resistance mechanisms.
During 2005, Rib-X expects to initiate
Phase I studies for at least one clinical
candidate from its most advanced program.
This program (the Rc-01 program) has
yielded attractive, orally active
compounds with attributes appropriate
for therapeutic applications in either
the hospital Gram-positive or community
respiratory tract infection marketplace.
Rib-X’s iterative approach has
yielded several distinctive chemical
classes in addition to those defined
by the Rc-01 program. The Company
is currently well-positioned to develop
a pipeline of differentiable products
that are expected to address distinct
markets for the treatment of bacterial
infections.
For more information on the ribosome
and the Rib-X mission, please visit
the Company website at http://www.rib-x.com.
Contacts
Rx Communications Group
Rhonda Chiger (investors)
917-322-2569
|
